iBio Grants Rights To Use iBioLaunch Platform
The project is expected to be managed by Fraunhofer USA Center for Molecular Biotechnology (CMB) pursuant to the long-term agreement between iBio and CMB for advancement of the
Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one month to one year across the EU and European Economic Area.
Sun Pharmaceutical said that these generic Bupropion Hydrochloride extended release tablets are equivalent to GlaxoSmithKline’s Wellbutrin SR extended release tablets and includes three strengths: 100mg, 150mg and 200mg.